Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?
Adam S. Crystal and Alice T. Shaw
See article p. 4682

MicroRNA Dissects Out Dangerous Pancreatic Cysts from All the Rest
Ryan M. Thomas and Jason B. Fleming
See article p. 4713

New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
Marc Ladanyi, Marjorie G. Zauderer, Lee M. Krug, Tatsuo Ito, Robert McMillan, Matthew Bott, and Filippo Giancotti

The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Elias Pean, Sigrid Klaar, Eva Gil Berglund, Tomas Salmonson, Jeanett Borregaard, Kenneth F. Mackay, Eitan Amir, and Geoffrey Liu

Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization
J. Jack Lee, Nan Chen, and Guosheng Yin

Molecular Pathways: Targeting the TGF-β Pathway for Cancer Therapy
Anna L. Smith, Tyler P. Robin, and Heide L. Ford

Optimizing Cancer Treatments to Induce an Acute Immune Response: Radiation Abscopal Effects, PAMPs, and DAMPs
Charles M. Ludgate

Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
Lawson Eng, Abul Kalam Azad, Steven Habbous, Vincent Pang, Wei Xu, Anke H. Mailland-van der Zee, Sevtap Savas, Helen J. Mackay, Eitan Amir, and Geoffrey Liu

Promising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions
James J. Steinhardt and Ronald B. Gartenhaus

Survival Signals and Targets for Therapy in Breast Implant–Associated ALK–Anaplastic Large Cell Lymphoma
Melissa G. Lechner, Carolina Megiel, Connor H. Church, Trevor E. Angell, Sarah M. Russell, Bikki B. Sevell, Julie K. Jang, Garry S. Brody, and Alan L. Epstein

Chromosome 5q Loss in Colorectal Flat Adenomas
Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

Kurtis D. Davies, Anh T. Le, Mariana F. Theodoro, Margaret C. Skokan, Dara L. Aisner, Eamon M. Berge, Luigi M. Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli, Marco Alloisio, Armando Santoro, D. Ross Camidge, Marileila Varella-Garcia, and Robert C. Doebele

Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation

Zhenfeng Duan, Jianming Zhang, Edwin Choy, David Harmon, Xianzhe Liu, Petur Nielsen, Henry Mankin, Nathanael S. Gray, and Francis J. Hornicek

The Pivotal Role of Integrin β1 in Metastasis of Head and Neck Squamous Cell Carcinoma

Dongsheng Wang, Susan M€uller, A.R.M. Ruhul Amin, Donghai Huang, Ling Su, Zhongliang Hu, Mohammad Aminur Rahman, Sreenivas Nannapaneni, Lydia Koenig, Zhengjia Chen, Mourad Tighiouart, Dong M. Shin, and Zhuo G. Chen

Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

Lapo Alinari, Courtney J. Prince, Ryan B. Edwards, William H. Towns, Rajeswaran Mani, Amy Lehman, Xiaoli Zhang, David Jarjoura, Li Pan, Robert A. Baiochi, and David M. Lucas

Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6


Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model

Katharina Fraedrich, Jörg Schrader, Harald Ittrich, Gunhild Keller, Artur Gontarewicz, Verena Matzat, Arno Kromminga, Andrea Pace, Jürgen Moll, Michael Blüker, Ansgar W. Lohse, Dieter Horsch, Tim H. Brummendorf, and Daniel Benten

Role of Hedgehog Signaling in Malignant Pleural Mesothelioma

Yandong Shi, Ubiratan Moura, Isabelle Opitz, Alex Soltermann, Hubert Rehrauer, Svenja Thies, Walter Weder, Rolf A. Stahel, and Emanuela Felley-Bosco

An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas


Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Claire Fahren, Naoya Mimura, Kathryn Bobh, Sun-Young Kong, Gülü Gorgun, Diana Cirstea, Yiguo Hu, Jiro Minami, Hirotu Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D. Carrasco, Yu-Tzu Tai, Paul G. Richardson, Teru Hideshima, and Kenneth C. Anderson

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Johannes M. Heuckmann, Hyatt Balke-Want, Florian Malchers, Martin Peifer, Martin L. Kos, Mirjam Koker, Lydia Meder, Christine M. Lovly, Lukas C. Heukamp, William Pao, Ralf Küppers, and Roman K. Thomas

See commentary p. 4479

HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCα Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy

Kuen-Tyng Lin, Yi-Wei Wang, Chiu-Tong Chen, Chun-Ming Ho, Wen-Hui Su, and Yuh-Shan Jou
IMAGING, DIAGNOSIS, PROGNOSIS

4702

Epstein-Barr Virus Infection and Expression of B-cell Oncogenic Markers in HIV-Related Diffuse Large B-cell Lymphoma
Chun Chao, Michael J. Silverberg, Otoniel Martinez-Maza, Margaret Chi, Donald I. Abrams, Reina Haque, Hongbin D. Zha, Michelle McGuire, Lanfang Xu, and Jonathan Said

4713

miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts
Hanno Matthaei, Dennis Wylie, Maura B. Lloyd, Marco Dal Molin, Jon Kemppainen, Skye C. Mayo, Christopher L. Wolfgang, Richard D. Schulick, Laura Langfield, Bernard F. Andruess, Alex T. Adai, Ralph H. Hruban, Anna E. Szafranska-Schwarzbach, and Anirban Maitra

CANCER THERAPY: CLINICAL

4753

Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Yu Imamura, Tepppei Morikawa, Xiaoyun Liao, Paul Lochhead, Aya Kuchiba, Mai Yamauchi, Zhi Rong Qian, Reiko Nishihara, Jeffrey A. Meyerhardt, Kevin M. Haigis, Charles S. Fuchs, and Shuji Ogino

4764

Phase I Pharmacokinetic/ Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Andres Cervantes, Elena Elez, Desamparados Roda, Jeffrey Ecsedy, Teresa Macarulla, Karthik Venkatakrishnan, Susana Roselló, Jordi Andreu, JungAh Jung, Juan Manuel Sanchis-Garcia, Adelaida Perea, Inma Blasco, Laura Maños, José-Alejandro Pérez-Fidalgo, Howard Fingert, Jose Baselga, and Josep Tabernero

4775

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
E. Claire Dees, Roger B. Cohen, Margaret von Mehren, Thomas E. Stinchcombe, Hua Liu, Karthik Venkatakrishnan, Mark Manfredi, Howard Fingert, Howard A. Burris III, and Jeffrey R. Infante

4785

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
### Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors


### First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors


### A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer


### A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma


### Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid


### Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Jooeun Bae, Robert Smith, John Daley, Naoya Mimura, Yu-Tzu Tai, Kenneth C. Anderson, and Nikhil C. Munshi

### Biomarkers in Hepatocellular Carcinoma—Letter

Nicola Personeni, Lorenza Rimassa, and Armando Santoro